Multiple Myeloma

Patient Profile 3: A 58-Year-Old with IgG Kappa Multiple Myeloma

In the setting of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider how risk status may affect the selection of induction therapy.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Key Updates from the GRIFFIN Trial in Multiple Myeloma

Experts present the case of a 58-year-old patient with IgG kappa multiple myeloma and offer their initial impressions.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Patient Profile 1: A 45-Year-Old with Transplant-Eligible Multiple Myeloma

Experts on multiple myeloma discuss recent updates from the GRIFFIN trial on patients with transplant-eligible multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Quadruplet Induction Therapy in Patients With Transplant-Eligible NDMM

A panel of clinical experts presents the case of a patient with high-risk multiple myeloma (MM) who underwent transplant.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Treatment Duration and Maintenance Therapy in NDMM

Shared insight on the advent of quadruplet therapy regimens in the induction setting of transplant-eligible newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma

Clinical insights on treatment duration and the decision to place patients with newly diagnosed MM on maintenance therapy.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

June 15th 2023

Abdullah Khan, MBBS, explains the current data on bispecific T-cell engaging antibodies for the treatment of relapsed multiple myeloma.

Available Treatment Options for Patients with Relapsed Multiple Myeloma

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

June 15th 2023

Ashley Rosko, MD, presents the case of a 72-year-old woman with relapsed multiple myeloma for discussion.

Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives

The panel discusses how they would approach the treatment of a patient with relapsed/refractory MM who progresses on BCMA-targeting bispecifics.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US

The panel discusses the approach to step-up and treatment dosing for bispecifics in their respective health care systems.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Managing Hematological Toxicities Associated with Bispecifics in MM

Expert hematologist-oncologists discuss how they incorporate teclistamab in their clinical practice as well as variations in access to bispecifics and CAR T-cell therapy.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab

Experts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Treatment Considerations With Bispecifics in Multiple Myeloma

Melissa Alsina, MD, presents the case of a 39-year-old patient with multiple myeloma who has disease progression after initially responding to teclistamab.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Multiple Myeloma: Overview of an Evolving Treatment Landscape

Panelists provide a broad-view perspective on established treatment pathways with bispecifics in multiple myeloma and the most prevalent challenges tied to this class of therapy.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

FDA Grants Fast Track Designation to Inobrodib in R/R Multiple Myeloma

Moderator Cesar Rodriguez, MD, spearheads a discussion on the current state of the multiple myeloma treatment paradigm with a focus on bispecifics in the multiply relapsed setting.

$Inobrodib is under investigation as a treatment for patients with relapsed/refractory multiple myeloma and other hematologic malignancies in a phase 1/2a trial.$

Russ Conroy

MonumenTAL-1: Data Updates of Non-BCMA Bispecifics in MM

Inobrodib is under investigation as a treatment for patients with relapsed/refractory multiple myeloma and other hematologic malignancies in a phase 1/2a trial.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

MagnetisMM-1: Data Updates of Anti-BCMA Bispecifics in MM

Shared insight from Rafael Fonseca, MD, on data from MonumenTAL-1 and the use of talquetamab therapy in patients with relapsed/refractory multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Data Updates From GRIFFIN and MASTER in Transplant-Eligible NDMM

Expert perspectives from Joselle Cook, MBBS, on use of elranatamab in relapsed/refractory multiple myeloma based on data from the MagnetisMM-1 trial.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Triplet and Quadruplet Induction Regimen Options for Patients With Transplant-Eligible NDMM

David Witt, MD, details the design and outcomes of the GRIFFIN study in newly diagnosed multiple myeloma.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Natalia Neparidze, MD, reviews the available induction treatment options for patients with newly diagnosed multiple myeloma (NDMM).

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

Bispecifics in Relapsed/Refractory Multiple Myeloma: Adverse Event Management

Experts in multiple myeloma management review the role of CAR T-cell therapy in patients with relapsed/refractory disease.

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

Cilta-Cel Yields Long-Term Efficacy in Pretreated R/R Multiple Myeloma

Focused discussion on mitigating and managing the adverse event profiles of bispecifics in relapsed/refractory multiple myeloma.

Russ Conroy

June 11th 2023

A single infusion of ciltacabtagene autoleucel produces a manageable safety profile among patients with relapsed/refractory multiple myeloma in the phase 1b/2 CARTITUDE-1 study.

Teclistamab Combo Yields Responses, No New Toxicity in R/R Multiple Myeloma

Russ Conroy

June 10th 2023

Findings from the phase 1b RedirecTT-1 study may support initiating larger studies evaluating teclistamab plus talquetamab for patients with relapsed or refractory multiple myeloma.

$Results from the phase 2 DARIA trial found an improved overall response rate in patients given daratumumab, ixazomib, and dexamethasone with relapsed/refractory multiple myeloma who were previously treated with lenalidomide.$

Daratumumab Combo Yields Responses in Pretreated R/R Multiple Myeloma

Ariana Pelosci

Triplet Induction Therapy in Patients With Transplant-Eligible NDMM

Results from the phase 2 DARIA trial found an improved overall response rate in patients given daratumumab, ixazomib, and dexamethasone with relapsed/refractory multiple myeloma who were previously treated with lenalidomide.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

MAIA Trial: DRd in Patients with Newly Diagnosed MM

Focused discussion on the historical use of triplet regimens as induction therapy in transplant-eligible newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Overview on Risk Stratification in Multiple Myeloma

Insights gleaned from the MAIA trial, which researched daratumumab, lenalidomide, and dexamethasone in patients with newly diagnosed MM.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Thomas Atkinson, MD;Ernest C. Quintin, MD

Patient Profile 2: A 74-Year-Old with Transplant-Ineligible NDMM

Opening its discussion on the management of multiple myeloma, a panel of experts from Ochsner Health reviews risk stratification strategies via NCCN and mSMART guidelines.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN